Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

The Japan Self-Defense Forces have placed an order for 17 CH-47JA Block II Chinooks (Extended Range) transport helicopters, ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment. The FDA has approved a label expansion ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Our editors also may be in touch with follow-up questions. T-Mobile has been in the telecommunications business since 1994 when it was known as VoiceStream Wireless. Today, it’s one of the ...

T-Mobile is the third-largest wireless carrier in the United States, with its popularity largely down to its network coverage and the wide range of tempting offers available. They span from T ...

Secondly, Stoloff considers the cuts of T-shirts by asking a few questions, such as: “Are you wearing this in the summer or layered in the winter under a blazer? Do you want a boxy, boy fit or a ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

Democrat lawmakers and some lawyers criticized the freeze, noting the executive branch doesn’t have the power to unilaterally change the disbursement of congressionally appropriated funds.

Nearly identical results were observed in the smaller group of people with ultralow HER2 levels, though the study wasn’t powered to detect a statistical difference on that measure. The study hasn’t ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results. The FDA has granted ...